Servier Canada
Oncaspar®
ONCASPAR logo; ONCASPAR pegaspargase injection.

Patient Profiles

Meet Max‡ — a patient with ALL

30 years of age1

Initial presentation1

  • Max was undergoing ONCASPAR® treatment for ALL
  • Unfortunately, he developed grade 1 hypersensitivity to ONCASPAR® during the course of treatment.

Treatment plan1

  • Max’s doctor reduced the ONCASPAR® infusion rate by 50%, and monitored him for an hour after infusion
  • Max’s doctor also initiated a therapeutic drug monitoring plan to monitor his allergic reactions

Max was able to remain on and complete treatment for ALL1

Photograph of Max, a 30-year-old man.

Consider ONCASPAR® as part of the chemotherapy regimen for your patients like Max

aBFM: augmented Berlin-Frankfurt-Münster; ALL: acute lymphoblastic leukemia; BSA: body surface area; CNS: central nervous system; CSF: cerebrospinal fluid; DFCI: Dana-Farber Cancer Institute; ELISA: enzyme-linked immunosorbent assay; IM: intramuscular; IV: intravenous; PD: pharmacodynamics; PK: pharmacokinetics; NCCN: National Comprehensive Cancer Network®; TDM: therapeutic drug monitoring.

* Clinical significance has not been established.

† Comparative clinical significance has not been established.

‡ Fictitious cases. May not be representative of all patients.

§ Native E. coli L-asparaginase is not available in Canada.

References: 

  1. ONCASPAR® Product Monograph. Servier Canada. August 20, 2024.
  2. ONCASPAR_CPID Redacted.
  3. ASPARLAS® Product Monograph. Servier Canada. March 8, 2024.
  4. RYLAZE™ Product Monograph. Jazz Pharmaceuticals Canada Inc.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed November 8, 2024.
  6. Vrooman LM et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.
Back to top

Stay Connected with Servier Canada

Stay up to date on disease information, treatment options, our products, and patient support programs.

Sign Up